Sign up to save your podcasts
Or
Share From Bankruptcy to $100B FCF (e2615)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
From Bankruptcy to $100B FCF (e2615)
NVIDIA has evolved from a near-bankrupt GPU maker into the most dominant force in computing infrastructure. This week we unpack the "process power" framework that explains why, and ask whether Eli Lilly can replicate the same playbook in pharma.
[00:00] Exhibit C: Oil Markets & Iran CeasefireIf the ceasefire holds, global production declines ~1M bbl/day. Demand stays flat at 103M. Average oil price for the rest of 2026 likely lands around $80. Higher oil prices paradoxically push nat gas lower via increased Permian associated gas production.
[03:00] Exhibit B: Natural Gas OutlookHenry Hub at $2.86 prompt with $3.70 for 2027. Permian associated gas growing from 23 to 25 Bcf/d this year. Waha hub negative since January. Hoping gas holds $3.50-$4.00 range but oversupply risk persists.
[04:23] Exhibit A: Fiscal & Defense SpendingWar supplemental request dropped from $200B to $80B. Defense budget proposal at $1.5T vs. current ~$900B run rate. Tariff revenue only ~$300B of $5.5T total federal revenue. Deficit must decline as a percentage of GNP — no other path.
[08:27] Modern Warfare & Cost ReductionAutonomous drone-based interceptors replacing $10M missiles. Future defense procurement shifts from stockpile building to productive capacity and supply chain resilience. Iran's drone supply to Russia now disrupted.
[10:00] NVIDIA Deep Dive: Process PowerHamilton Helmer's "Seven Powers" framework applied to NVIDIA. The real moat isn't CUDA's network effect — it's the 9-month iteration cadence established in 1997 when Jensen acquired a hardware emulator on the brink of bankruptcy. That process advantage compounded over a decade when nobody was watching.
[14:00] NVIDIA's Vertical IntegrationFrom DGX-1 with Intel Xeon CPUs to today's full-stack offering: NVIDIA GPUs, NVIDIA CPUs, Mellanox networking (acquired 2019), and Groq LPUs. They sell complete data center aisles, capturing margin that Intel shared with Dell and Broadcom.
[16:00] Intel's Cautionary TaleIntel voluntarily gave up Moore's Law process leadership because next-gen economics didn't satisfy shareholders. Now at $50B revenue with zero free cash flow. NVIDIA's position is stronger than Intel's ever was.
[19:00] NVIDIA's Next FrontiersJetsons robotics chips (a decade in development), CUDA Q2Q quantum computing simulators. NVIDIA has taken the CUDA playbook wide across verticals — payoffs expected over the next few decades.
[20:00] Taiwan Semiconductor DependencyTSMC sales up 30% monthly. Samsung's operating profit tripled. Elon bringing Intel into Tesla's Terra Fab project with Samsung. TSMC in monopoly position, deliberately under-building capacity.
[21:45] AI Compute Demand: Anthropic & xAIAnthropic's token production showing exponential growth since AI agents launched. New model cost ~$10B to train — likely first fully trained on Blackwells. xAI planning models up to 10 trillion parameters.
[23:22] Pharma Tariffs: 100% on Active IngredientsTargets China supply chain dependence. Extensive exemptions for orphan drugs, cancer therapies. 16 pharma companies have MFN agreements. 20% reduced rate for onshoring. Market reaction muted — this is a carrot, not a stick.
[25:21] Eli Lilly: Dominant but ExpensiveRevenue up 40% YoY, FCF up 80%. Trading at ~50x FCF — more expensive than NVIDIA's 40x. Oral GLP-1 pill is a competitive advantage, but barriers to entry are lower than semiconductors. Process power in biotech is rare and harder to sustain.
Subscribe to the Cash Flow Memo at telltales.us and download this week's data package covering 80+ companies across energy, tech, and healthcare.
This podcast and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future.
This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit telltales.substack.com
View all episodes
By by Top Mark Capital
5
66 ratings
NVIDIA has evolved from a near-bankrupt GPU maker into the most dominant force in computing infrastructure. This week we unpack the "process power" framework that explains why, and ask whether Eli Lilly can replicate the same playbook in pharma.
[00:00] Exhibit C: Oil Markets & Iran CeasefireIf the ceasefire holds, global production declines ~1M bbl/day. Demand stays flat at 103M. Average oil price for the rest of 2026 likely lands around $80. Higher oil prices paradoxically push nat gas lower via increased Permian associated gas production.
[03:00] Exhibit B: Natural Gas OutlookHenry Hub at $2.86 prompt with $3.70 for 2027. Permian associated gas growing from 23 to 25 Bcf/d this year. Waha hub negative since January. Hoping gas holds $3.50-$4.00 range but oversupply risk persists.
[04:23] Exhibit A: Fiscal & Defense SpendingWar supplemental request dropped from $200B to $80B. Defense budget proposal at $1.5T vs. current ~$900B run rate. Tariff revenue only ~$300B of $5.5T total federal revenue. Deficit must decline as a percentage of GNP — no other path.
[08:27] Modern Warfare & Cost ReductionAutonomous drone-based interceptors replacing $10M missiles. Future defense procurement shifts from stockpile building to productive capacity and supply chain resilience. Iran's drone supply to Russia now disrupted.
[10:00] NVIDIA Deep Dive: Process PowerHamilton Helmer's "Seven Powers" framework applied to NVIDIA. The real moat isn't CUDA's network effect — it's the 9-month iteration cadence established in 1997 when Jensen acquired a hardware emulator on the brink of bankruptcy. That process advantage compounded over a decade when nobody was watching.
[14:00] NVIDIA's Vertical IntegrationFrom DGX-1 with Intel Xeon CPUs to today's full-stack offering: NVIDIA GPUs, NVIDIA CPUs, Mellanox networking (acquired 2019), and Groq LPUs. They sell complete data center aisles, capturing margin that Intel shared with Dell and Broadcom.
[16:00] Intel's Cautionary TaleIntel voluntarily gave up Moore's Law process leadership because next-gen economics didn't satisfy shareholders. Now at $50B revenue with zero free cash flow. NVIDIA's position is stronger than Intel's ever was.
[19:00] NVIDIA's Next FrontiersJetsons robotics chips (a decade in development), CUDA Q2Q quantum computing simulators. NVIDIA has taken the CUDA playbook wide across verticals — payoffs expected over the next few decades.
[20:00] Taiwan Semiconductor DependencyTSMC sales up 30% monthly. Samsung's operating profit tripled. Elon bringing Intel into Tesla's Terra Fab project with Samsung. TSMC in monopoly position, deliberately under-building capacity.
[21:45] AI Compute Demand: Anthropic & xAIAnthropic's token production showing exponential growth since AI agents launched. New model cost ~$10B to train — likely first fully trained on Blackwells. xAI planning models up to 10 trillion parameters.
[23:22] Pharma Tariffs: 100% on Active IngredientsTargets China supply chain dependence. Extensive exemptions for orphan drugs, cancer therapies. 16 pharma companies have MFN agreements. 20% reduced rate for onshoring. Market reaction muted — this is a carrot, not a stick.
[25:21] Eli Lilly: Dominant but ExpensiveRevenue up 40% YoY, FCF up 80%. Trading at ~50x FCF — more expensive than NVIDIA's 40x. Oral GLP-1 pill is a competitive advantage, but barriers to entry are lower than semiconductors. Process power in biotech is rare and harder to sustain.
Subscribe to the Cash Flow Memo at telltales.us and download this week's data package covering 80+ companies across energy, tech, and healthcare.
This podcast and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future.
This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit telltales.substack.com